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Metastasis is the primary cause of mor-
bidity and mortality for patients with can-
cer. While it has been recognized for
many years that movement of neoplastic
cells is not a random
process, the molecular and
cellular mechanisms govern-
ing their movement, survival
through foreign tissue envi-
ronments, and parameters
for choosing and taking up
residence at a final destina-
tion have remained uncer-
tain. Several contrasting the-
ories have emerged to
explain metastatic specificity.
The “homing” theory sug-
gests that organs distal to
sites of primary malignancy
actively attract and/or arrest
(“trap”) malignant cells via
expression of adhesion
receptors, e.g., selectins, or
by secretion of soluble
chemotactic factors, e.g.,
chemokines. Indeed, there is
good experimental evidence
implicating chemokine recep-
tors and their ligands for the
chemoattraction aspect of
the homing theory (Muller et
al., 2001; Wilson and
Balkwill, 2002). In addition,
identification of “molecular
addresses” or adhesion
receptors on endothelial cells
in vascular beds of distal
organs that specifically trap
circulating malignant cells
supports the active “arrest”
view of homing (Borsig et al.,
2002; Laakkonen et al.,
2002). In contrast, the “fertile
soil” theory proposes that different organ
environments provide optimal growth
conditions for specific circulating cell
types. Since underlying mechanisms
supporting these theories are not mutu-
ally exclusive, it seems likely that distinct
mechanisms/molecules might govern a
malignant cells journey to an ectopic 
tissue, separate from those
regulating its growth and/or
survival once its destination
has been achieved. An excit-
ing observation by Shibuyu
and colleagues (Hiratsuka et
al., 2002 [this issue of Cancer
Cell]) provides some clues
into the later aspects of 
the metastatic cascade impli-
cating an extracellular metal-
loproteinase, e.g., matrix
metalloproteinase-9 (MMP9),
made by tumor-associated
macrophages (TAMs) and
alveolar endothelial cells, in
microenvironmental remodel-
ing necessary for metastatic
cell survival in the lung.
Tumor cells produce 
various cytokines and
chemokines that attract
leukocytes (macrophages,
neutrophils, dendritic cells,
eosinophils, and mast cells)
that are variably loaded 
with molecules affecting pri-
mary neoplastic growth, e.g.,
cytokines, cytotoxic media-
tors, serine-, cysteine-, and
m e t a l l o - p r o t e a s e s ,  
membrane-perforating agents,
and soluble mediators of cell
killing, such as tumor necro-
sis factor-α (TNF-α), inter-
leukins (IL), and interferons
(IFNs) (Wilson and Balkwill,
2002). TAMs play a dual role
in neoplasms.Whereas TAMs
MMP9 potentiates pulmonary metastasis formation
Tumor cell dissemination to distant organ sites is a complex process involving multiple cell types, soluble growth factors,
adhesion receptors, and tissue remodeling. A new study in this issue of Cancer Cell shows that MMP9-expressing tumor-
associated macrophages play a key role in prepping premetastatic sites for eventual malignant cell growth in a manner
dependent upon vascular endothelial growth factor receptor-1 (VEGFR-1).
Figure 1. A model for the role of tumor-associated macrophages and
MMP9 in priming premetastatic tissue
Macrophages (Mφ) are recruited to sites of malignant growth. Upon
activation by primary tumor (PT) cells, activated macrophages (Mφ*)
expressing MMP9 then reenter the circulation and induce MMP9
expression in (alveolar) endothelial cells (Alv. EC) in a VEGFR-1-
dependent manner, thereby prepping premetastatic tissue for malig-
nant cell colonization. Distal organs harboring low-level VEGFR-1
expression are not suitable environments for metastatic growth and
fail to induce MMP9 expression in response to the presence of activat-
ed macrophages.
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may kill neoplastic cells following activa-
tion by IL-2, IFN, or IL-12, they produce a
number of potent angiogenic and lym-
phangiogenic growth factors, cytokines,
and proteases that potentiate neoplastic
development. The functional significance
of TAM recruitment to developing neo-
plasms was established by intercrossing
transgenic mice susceptible to mamma-
ry cancer (PyMT mice) with mice con-
taining a recessive null mutation in the
colony stimulating factor-1 (CSF-1) gene
(Csf1op) (Lin et al., 2001). Whereas
absence of CSF-1 during early neoplas-
tic growth was without consequence,
development of late-stage invasive carci-
noma and their metastatic pulmonary
derivatives were significantly attenuated.
The key difference between PyMT mice
and PyMT/Csf1op/Csf1op mice was in the
failure to recruit mature macrophages
into neoplastic tissue in the absence of
CSF-1, implying that circulating
macrophages and molecule(s) they
secrete are necessary for productive
metastatic growth. Studies by Hiratsuka
et al. (2002) now provide evidence that
macrophages are potentiators of lung
metastases through MMP9 and vascular
endothelial cell receptor-1 (VEGFR-1)-
dependent mechanisms (Figure 1).
Using a mouse model of experimen-
tal metastasis formation, Hiratsuka et al.
(2002) have reported that following
recruitment to sites of primary tumor
growth, TAMs circulate to distal organs.
Distal organs exhibiting low-level expres-
sion of VEGFR-1 fail to induce MMP9 in
response to TAM presence and are
therefore not suitable environments for
subsequent metastatic cell growth. On
the other hand, distal organs that are
VEGFR-1-positive and contain a popula-
tion of endothelial cells capable of induc-
ing expression of MMP9 above that sup-
plied by circulating TAMs are fertile sites
for productive metastatic growth. While
induced expression of the VEGFR-1 lig-
and VEGF-A does not appear to be
involved, presence of an active VEGFR-
1 tyrosine kinase domain is necessary;
thus, it seems reasonable based on pre-
vious reports (Bergers et al., 2000) that
activated MMP9 releases matrix-
sequestered VEGF-A, rendering it
bioavailable for interaction with its recep-
tors and thereby stimulating efficient 
vascular remodeling and angiogenesis
necessary for metastatic cell growth and
survival. Administration of a synthetic
metalloproteinase inhibitor (BB-94)
attenuates metastatic growth in the lung
in this model, suggesting that the enzy-
matic activity of MMP9 is also a neces-
sary component of the pathway.
While VEGF-A is known to be a
matrix-sequestered molecule, it is likely
that other growth factors, cytokines, and
perhaps chemokines may similarly have
limited bioavailability characteristics
based on their affinities toward diverse
matrix molecules. Chemokines are cer-
tainly involved in regulating chemotaxis
of leukocytes (Wilson and Balkwill, 2002)
and are now also known to impart organ-
specific metastatic potential on
chemokine receptor-positive neoplastic
cells (Muller et al., 2001). Thus, one out-
standing question is whether MMP9 also
regulates the bioavailability characteris-
tics of lung-specific chemokines involved
in recruiting malignant cells, or alterna-
tively, whether it regulates the activities
of an adhesion receptor of the selectin
family necessary for “trapping” malignant
cells as they circulate.
The current report by Hiratsuka et al.
(2002) offers a new perspective on the
multifaceted activities of MMP9 and the
role of TAMs in prepping a distal organ
for arrival and eventual metastatic colo-
nization. Historical literature reporting on
MMP9 function(s) in vitro has provided a
compelling story implicating MMP9 as a
rate-limiting extracellular protease
involved in cell migration across base-
ment membranes. Likewise, the work by
Hiratsuka et al. (2002) also reveals a role
for MMP9 in facilitating tumor cell inva-
sion; however, it is not clear if this is a
mechanistic role or if MMP9 activity cre-
ates an environment amenable for
migration. Studies of cellular invasion in
tumor-prone mouse models harboring
homozygous null deletions in the MMP9
gene or in animals (or humans) treated
with broad spectrum MMP inhibitors do
not suffer from impaired migratory or
invasive behavior of malignant cells
(Bergers et al., 2000; Coussens et al.,
2000, 2002). Instead, cells growing in
MMP9-deficient environments have
altered proliferative or differentiation
capacity, largely due to altered growth
factor or survival factor bioavailability
(Bergers et al., 2000; Coussens et al.,
2000; Liu et al., 1998; Vu et al., 1998). In
sum, the combined implication of this
data suggests that TAM-induced MMP9
expression, in alveolar endothelial cells
as well as in TAMs, fertilizes the soil nec-
essary for secondary malignant cell
growth, dependent upon the presence
and activation of the VEGF-VEGFR sig-
naling cascade.
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